1. [The treatment of colonic and ovarian cancer with radioactive monoclonal antibodies against the CA l9-9 and CA 125 antigens].
- Author
-
Graef A, Romero MA, González M, Pierzo JA, Sosa R, and Altamirano P
- Subjects
- Adenocarcinoma immunology, Adult, Aged, Aged, 80 and over, Antigens, Tumor-Associated, Carbohydrate blood, Carcinoembryonic Antigen blood, Colonic Neoplasms immunology, Cystadenocarcinoma immunology, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Ovarian Neoplasms immunology, Adenocarcinoma radiotherapy, Antibodies, Monoclonal therapeutic use, Antigens, Tumor-Associated, Carbohydrate immunology, Colonic Neoplasms radiotherapy, Cystadenocarcinoma radiotherapy, Iodine Radioisotopes therapeutic use, Ovarian Neoplasms radiotherapy, Radioimmunotherapy methods
- Abstract
The age of monoclonal antibodies arose with the papers by Köhler and Milstein in 1975. By means of a fusion between a neoplastic cell with one which produced a specific antibody they obtained a hybrid or clonal cell. Five years later, Nadler et al issued the first report of a patient with lymphoma treated with monoclonal antibodies. After the first announcement, diverse research centers have reported the clinical results obtained in various neoplasias treated with radioactive monoclonal antibodies directed against antigens associated with neoplasias, as well as non-specific tumoral antigens, including lymphomas, melanomas and cancers of the colon, ovary and breast.
- Published
- 1992